Patent intelligence · US
US 11845752
Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B
Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B
Patent details — US 11845752
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 19, 2023
- Expiration
- Dec 14, 2043
- Applicant
- Aligos Therapeutics, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K45/06
Quick answer
US 11845752 (Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B) is held by Aligos Therapeutics, Inc.. Status: granted. Granted Dec 19, 2023. Expires Dec 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aligos Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K45/06
More from Aligos Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384779
Bicyclic compounds
granted -
US 12252481
Anti-viral compounds
granted -
US 12180192
Modulators of THR-β and methods of use thereof
granted -
US 12129469
Modified short interfering nucleic acid (siNA) molecules and uses thereof
granted -
US 12065428
Anti-viral compounds
granted -
US 12018015
Methods and compositions for targeting PD-L1
granted -
US 11957683
Bicyclic compounds
granted -
US 11952374
Bicyclic compounds
granted
Frequently asked questions
What is US patent 11845752?
US 11845752 (Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B) is held by Aligos Therapeutics, Inc.. Status: granted. Granted Dec 19, 2023. Expires Dec 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11845752?
Aligos Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 32 pharmaceutical patents for this assignee.
When does US 11845752 expire?
Our index shows an expiration date of Dec 14, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.